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Abstract: Both the chemistry and consequences of the nonenzymatic reaction between reducing sugars and reactive amino groups of amino 
acids, peptides and proteins (known as the Maillard reaction), have received considerable attention in food and health science fields. This initial 
reaction results in Amadori and similar products formation, followed by degradation to advanced glycation end products (AGEs). It is well 
established that AGEs are associated with color and odor of thermally processed or stored food, as well as with pathogen products in a number 
of diseases. The model systems of early stage Maillard reaction products (MRP) were prepared between endogenous opioid peptide leucine 
enkephalin (1) and D-glucose / D-glucuronic acid. The complexation ability of prepared MRP with metal ions (Ca2+, Zn2+, Al3+, Pb2+ and Cu2+) was 
investigated and compared to the complexation ability of parent peptide using ECD and FTIR spectroscopic measurements. 
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INTRODUCTION 
RANSITION metal ions are found in living organisms,  
coordinated to different biomolecules and participat-
ing in many biochemical reactions where they play a crucial 
role. Carbohydrates, although involved in many biochemi-
cal processes, immunological events, and pathological  
conditions, exhibit relatively poor coordinating properties 
and form weak complexes with metal ions, however, an  
increased metal-binding ability has been linked to the  
glycated proteins formed in Maillard reaction.[1–4] In such  
reversible reaction, reducing sugars react with amino acids, 
peptides or proteins, producing Amadori, Heyns, and other 
similar compounds, which can further form irreversible AGE 
(Advanced Glycation End) products. There is accumulating 
evidence for the ability of Maillard reaction products (MRP) 
to complex metal ions.[5] It is well known that metal ions can 
form complexes of various properties with MRPs, oxidize 
Amadori compounds as well as their derivatives, and  
catalyze further interactions of these compounds.[5–7] In  
addition, transition elements accelerate the formation of 
Amadori compounds, as well as their polymerization pro-
ducts during the final stage of the Maillard reaction.[6–14] 
Nevertheless, the information about MRP complexes and 
whether complexations of individual MRPs are likely to 
influence internal metabolism in vivo is not currently available. 
 We know that the type of cation is important for the 
chelating ability of MRPs, as well as its role in the stability 
of the complexes formed, and the accumulation of 
chromophores in reaction systems.[5,15,16] Moreover, the 
browning reaction rate studied in heated solutions of 
Amadori compounds depends not only on the amounts of 
metal salts added, but also on the valence of the 
cations,[6,17] and pH of the solution.[18] 
 Since formations of metal complexes are associated 
with different but unknown MRP ligands, we have explored 
the ability of several MRPs with known structures to  
complex with several biologically relevant metal ions.[19] For 
instance, the importance of copper in human metabolism is 
its involvement in oxidative processes.[20–25] Aluminum was 
chosen due to its high presence in the environment and  
extensive use in modern daily life (diets and medication). 
However, there is no known physiological role for alumi-
num within the body and hence this metal may strongly  
alter normal cellular metabolic pathways and produce 
adverse physiological effects.[26] Calcium is important for 
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healthy bones, but the question is if it is responsible for  
kidney stones formation, and calcification of blood vessels. 
The strong and selective binding of calcium(II) ions to  
proteins is related to the regulation of many physiological 
functions.[27] Zinc is known to be essential for all highly 
proliferating cells in the human body, especially the  
immune system, but high dosage of zinc evokes the same 
negative effects as those observed with zinc deficiency.[28] 
The toxicological effects of lead include neurotoxicity, 
carcinogenicity, reproductive toxicity, and neurobeha-
vioral/developmental effects.[29] Thus, investigation con-
cerning difference in complexation ability for these metal 
ions of natural peptides and their MRPs is of essential 
importance. The ability of complexation of Zn2+, Al3+, Ca2+, 
Pb2+ and Cu2+ multivalent cations with endogenous opioid 
peptide Leu-enkephalin (1)[30,31] and four different Leu-
enkephalin MRPs 2–5 was investigated. Electronic circular 
dichroism (ECD) and Fourier transform infrared (FTIR) 
spectroscopy, as complex spectroscopic methods, were 
used to characterize the conformation and the cation-
induced conformational changes of peptides 1–5. 
 
EXPERIMENTAL 
Leu-enkephalin (1) was purchased from Bachem. Amadori 
compounds, N-(1-deoxy-D-fructos-1-yl)-L-tyrosylglycylgly-
cyl-L-phenylalanyl-L-leucine (2) and N-(1-deoxy-D-fructo-
furanos-1-yl-uronic acid)-L-tyrosyl-glycylglycyl-L-phenylala-
nyl-L-leucine (4) were synthesized under the conditions 
described by Horvat et al. (1998)[32] and Horvat et al. 
(2007).[33] Imidazolidinone derivative, N-{[2-(D-gluco-penti-
tol-1-yl)-4- (4 - hydroxybenzyl) - 5 - oxoimidazolidin-1-yl]ace-
tyl}glycyl-L-phenylalanyl-L-leucine (3) was obtained as 
described by Roščić and Horvat (2006).[34] N-[2-(4-hy-
droxybenzyl) - 2 - (3-hydroxypyridin - 1 - ium)ethanoyl]glycylgly-
cyl-L-phenylalanyl-L-leucine (5) was obtained as described 
by Horvat et al. (2007).[33] All compounds were desalted 
using an octadecylsilica solid-phase extraction (SPE) 
cartridge (500 mg, 2.8 mL). The following compounds all 
purchased from Sigma-Aldrich were used as metal ions 
source: Al(ClO4)3 × 10H2O, Ca(ClO4)2 × 4H2O, Cu(ClO4)2 × 6H2O, 
Zn(ClO4)2 × 6H2O and Pb(ClO4)2 × 3H2O. ECD titrations were 
performed at peptide : metal ratios ranging from 1 : 0.25 to  
1 : 5, by adequately mixing stock solutions of peptides (0.4 mM) 
and different metal ions (25 mM). The concentrations of 
peptides were between 0.2–0.4 mg mL–1 and concentrations of 
metal salts between 1–6 mg mL–1. The solvents for the spec-
troscopic studies were 2,2,2-trifluoroethanol (TFE; Aldrich, 
NMR grade), and double distilled water. 
ECD Measurements 
Electronic circular dichroism (ECD) spectra were recorded 
on a Jasco J-810 spectropolarimeter  at room temperature 
in a quartz cell with 0.2 mm path length  in the 185–280 nm 
(far UV) and with 10.0 mm path length in the 250–320 nm 
(near-UV) region. The peptide:metal ratio is expressed with 
rcat = cation / peptide and titration was running at rcat = 
0.25–5. ECD band intensities are expressed in mean residue 
ellipcity ([Θ]MR; deg cm2 dmol–1). 
FTIR Measurements 
FTIR spectra of 2 cm–1 resolution were recorded on a Bruker 
Equinox 55 spectrometer equipped with liquid N2-cooled 
MCT detector. The spectra were obtained at room 
temperature in a CaF2 cell of 0.2 mm path length. The sample 
concentration in TFE (or a TFE solution containing 2, 8 or 12 
mM Ca perchlorate) was 4 mM in each measurement. The 
spectra were corrected with the background. 
 
RESULTS AND DISCUSSION 
ECD Spectroscopic Characterization of 
Compounds and Their Metal Complexes 
Investigation of the endogenous opioid peptide Leu-
enkephalin under Maillard reaction conditions (nonenzy-
matic glycation) lead to the chemical transformations of 
Leu-enkephalin (1) (Figure 1). Two glycation products 
resulted from the reaction of D-glucose (Glc) and Leu-
enkephalin (1) as early glycation products. The first product 
is Amadori compound 2 in which the linear peptide is 
alkylated at the N-terminal position by a 1-deoxy-D-fructose 
unit. The second product in the reaction is compound 3 
which has characteristic rigid 5-membered imidazolidinone 
ring. In this adduct an imidazolidinone moiety connects the 
acyclic sugar residue with the linear peptide chain. Early 
glycation products in the reaction of D-glucuronic acid 
(GlcA) and Leu-enkephalin are Amadori compound 4 and 
aromatic 3-hydroxypyridine derivative 5. 
 In aim to determine the complexation potential of 
compounds 1–5 first of all ECD spectra of these synthetic 
peptides were recorded (Figure 2). According to the 
spectrum and previous investigation it was concluded that 
Leu-enkephalin 1 is present in TFE as a mixture of 
conformers with no dominant recognizable conforma-
tion.[35,36] The ECD spectra of Amadori compounds 2 and 4 
do not differ significantly from that of 1 which suggests no 
strong difference in distribution of backbone conformers 
from peptide 1. The ECD spectrum of the imidazolidinone-
derivative 3 shows a broad positive band centered at  
λ ~ 206 nm suggesting the influence of imidazolidinone ring 
on the conformation of Leu-enkephalin. The 3-hydroxy-
pyridinium derivative 5 shows a markedly different ECD 
spectrum featuring with a weak positive band centered at 
~ 220 nm, a negative band at 202 nm and a positive one at 
191 nm due to structure of 3-hydroxypyridinium ring. It is 
 
 
 
 Z. MAJER et al.: Metal-Binding Ability of Leu-Enkephalin … 283 
 
DOI: 10.5562/cca2725 Croat. Chem. Acta 2015, 88(3), 281–287 
 
 
 
obvious that different MRPs of Leu-enkephalin have 
different effect on the structure of peptide 1, which can 
produce difference in peptide stability and activity.[7] ECD 
spectra in TFE of MRP peptides 2–5 were measured in the 
presence of different types of cations and at their 
different ratio to study the conformational effect / binding 
type of multivalent cations Zn2+, Al3+, Ca2+, Pb2+, and Cu2+. 
There have been many attempts to categorize various 
metal ions and anions to predict reactivity, solubility, etc. 
According to Pearson (1963)[37] Al3+ and Ca2+ are hard 
Lewis acids, Zn2+ is strong Lewis acid, Cu2+ and Pb2+ soft 
Lewis acids are in borderline; while carboxyl, amide and 
hydroxyl groups belong to the hard Lewis bases. Hard 
acids and bases are small, compact, and non-polarizable. 
Hard acids tend to bind to hard bases to form adducts with 
ionic character while soft acids tend to bind to soft bases 
and theirs adducts are more covalent in nature. In 
oligopeptides both terminal groups, the amide and 
carboxyl group and the functional side chain groups 
(carboxyl-, amino-, thioether-, thiyl-, imidazolyl group) are 
potential binding sites for cations. If the amino terminal 
group is free, the side chain primarily serves as anchor of 
metal ion. Since Al3+ and Ca2+ are strong Lewis acids  
and hard metals, they are expected to react with the  
O-donors, such as e.g. carboxylate ion (C-terminal or side 
chain COO–  of peptides), phenolate (Tyr(O–)) and also 
deprotonated hydroxyl group from carbohydrates to form 
glycopeptide-metal complexes. Zn2+ and Cu2+ ions can 
bind to the terminal amino and/or carboxyl groups 
(mostly they are labile). More stable complex (chelate-
type) is expected to form involving the terminal amino 
and either the neighboring amide carbonyl groups (in the 
case of Zn2+) or deprotonated amide nitrogen atom. The 
formation of complexes through peptide backbone will 
affect the character of the ECD spectra. 
 The aim of the present study was twofold: i) studying 
the ability of complexation of each compound 1–5 with 
various cations; ii)  comparison of the complexation ability 
of MRPs 2–5 with the ability of complexation of peptide 1. 
The cation-induced ECD spectral changes in spectra of 
peptides 1–5 were measured from “stable complexes” at 
rcat where increasing cation concentration caused no more 
ECD-changes. Compounds 2–5 as Amadori, imidazolidinone 
and 3-hydroxypyridinium derivatives of Leu-enkephalin (1) 
 
 
Figure 1. Formation of early glycation products of Leu-enkephalin (1) with glucose (Glc) and glucuronic acid (GlcA). 
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can give more potential cation-binding places then the 
corresponding parent peptide 1. 
 Leu-enkephalin 1 with the cations Pb2+, Cu2+ and Al3+ 
shows the adoption of more folded conformers stabilized 
by free carboxyl and/or side chain binding at rcat ≤ 1. These 
ECD spectra are characterized by a negative band near  
205 nm and positive bands near ~ 190 nm and 230 nm, 
suggesting βI/III turn-type (for a classification and ECD 
spectroscopic features of different types of turns see ref. 
38), while with Cu2+ an extra negative peak with weak 
intensity around 240 nm appeared. In the presence of Ca2+ 
all extremes are red shifted with ~ 5–10 nm (βII turn-type, 
Figure 2a), while with Zn2+ all peaks are more intense and 
broader indicating a lot of different turn-types. 
 Amadori compound 2 (Figure 2b) gave βI/III turn-
type, C-like spectrum with Ca2+ at rCa = 1 as a stable 
complex, with two negative bands above 205 and 218 nm 
and a positive band at ~ 195 nm.[37,38] With Zn2+ compound 
2 shows a spectrum marked by a strong positive band at  
~ 195 nm, a weaker one at ~ 225 nm and a strong, broad 
negative band centered at 208 nm. This spectral feature 
indicates the presence of a mixture of folded conformers, 
 
 
 
 
 
 
 
 
 
      
                                     
Figure 2. CD spectra of (A) Compound 1; (B) Compound 2; (C) Compound 3; (D) Compound 4; (E) Compound 5; and their 
complexes with Al3+, Ca2+, Zn2+, Cu2+ and Pb2+ ions. 
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mainly β- and γ- turn.[38] In the presence of Cu2+ the ECD 
spectrum shows a strong, very broad negative band 
centered at ~ 200 nm and a weaker one at ~ 240 nm. 
 Imidazolidinone compound 3 (Figure 2c) gave more 
or less βI/III turn-type C-like spectra with all cations except 
Al3+. The cation-induced ECD spectra of compound 3 (Figure 
2c) are generally marked by a very broad negative band 
between 200–230 nm with more overlapping extremes. Al3+ 
gave an unusual ECD shape which can suggest different 
complexation with the various functional groups.  
 In Amadori compound 4 (Figure 2d) free carboxylic 
acid can contribute to the complex formation but only 
subtle spectral effect with Ca2+ (rcat = 1), Al3+ (rcat = 0.5) and 
Pb2+ (rcat = 2) were observed. With Zn2+ and Cu2+ ions 
compound 4 shows the same spectral behavior as in the 
case of compound 2 which can be attributed to the Amadori 
structure but they have also similarity with compound 1. 
 In the solution of 3-hydroxypyridinium derivative 5 
(Figure 2e), all cations, except Ca2+, induce the same 
spectral character and the observed β-turn-type C-like 
spectra differ only in the relative band intensities which 
means that there is no complex formation with backbone 
amide carbonyl groups so there are no significant 
conformational changes. The only exception is Ca2+ which 
with 5 gave a broad and strong positive band at 190 nm, a 
strong negative band at ~ 215 nm and an additional weaker 
one at ~ 248 nm. This spectrum shows -sheet like features 
and it is not a typical “Ca-induced spectrum”, characteristic 
for many peptide-Ca2+ complexes, where the main features 
would be a weak positive band above 210 nm and a strong 
negative one at ~ 195 nm. [39] 
FTIR Spectroscopic Characterization of 
Compounds and Their Metal Complexes 
The infrared spectra of compounds 1–5 (Figure 3) were 
taken in TFE in the 1800–1500 cm–1 spectral region, which 
is mainly composed of bands due to νC=O(COOH), amide I, 
amide II and νas(COO–) vibrations. Absorption by the 
aromatic Tyr and Phe side chains also give contribution in 
this spectral region. The sharp component bends near 
1519, 1600 and 1616 cm–1 in the infrared spectra of all 
analyzed compounds are assigned to the ring vibrations of 
Tyr and Phe. Since FTIR measurements require much higher 
sample concentrations than ECD, which may induce 
 
 
 
 
 
 
 
      
                                     
Figure 3. FTIR spectra of (A) Compound 1; (B) Compound 2; (C) Compound 3; (D) Compound 4; (E) Compound 5; and their 
complexes with Ca2+ ion. 
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precipitation in the presence of certain metal ions 
(especially Al3+), a systematic study with all the metal ions 
was not possible. Based on its high biological relevance and 
considering the characteristic changes observed in the ECD 
spectrum, the FTIR based complexation studies were 
restricted to the Ca2+ ion. The infrared spectra of 
compounds 1–5 with Ca were taken at peptide-metal ratios 
for which the stable complexes were observed (Figure 3) 
according to the ECD spectra. Main difference observed in 
complex spectra compared to compounds alone were shifts 
from 1542 cm–1 to 1552 cm–1 in the amide II spectral region 
of compounds 1–3 and 5, while compound 4 does not show 
shift of this extreme which is in agreement with ECD 
spectrum of compound 4 with Ca2+ where no significant 
changes of spectrum shape was observed. The Ca2+-induced 
changes observed in the FTIR spectra of compounds 1–5 
are more subtle than those in ECD and do not provide 
sufficient information for a more detailed conformational 
interpretation in terms of possible types of folded 
structures. 
 
CONCLUSION 
In the case of short chain peptides containing aromatic 
amino acid residue, as Leu-enkephalin, ECD spectroscopy 
can give a good diagnostic of conformational changes (e.g. 
cations, solvent, temperature), but cannot discriminate 
well the  aromatic contribution from the conformational 
effect.[40,41] Binding of the cation to the free carboxylic 
group or OH-group of side chain of Tyr can stabilize the 
backbone conformation of the peptide, but cation-bindings 
to the backbone amide carbonyl groups can have higher 
influence to the conformational changes. It is known that 
the hard metals such as Ca2+ and Al3+ ions bind to the 
carboxyl group, phenolic side chain of Tyr and backbone 
amide carbonyl group. In TFE the cation-binding involves 
deprotonation of the C-terminus carboxyl group or hydroxyl 
Tyr side chain, or sugar hydroxyl group. The zwitter-ion 
formation enables this reaction. Appearance of the 
stronger spectral feature of π → π* at 195 nm may be 
attributed to folded structures stabilized by the cation. 
 The slight changes of the ECD shapes are similar in 
the case of Ca2+ and Al3+ with compounds 1, 2, and 4 at the 
same ratio. We suppose that these changes are only due to 
the modified distribution of the conformers. The ECD 
curves of compounds 3 and 5 with Ca2+ ion show 
characteristic conformational changes toward ordered 
structures. Complexation of compound 3 with Al3+ and Ca2+ 
results in ECD changes which might be interpreted as 
binding of both cations to the side chains and also to amide 
carbonyl(s) of the peptide backbone which results in 
appearance of different types of turns. Compound 5 with 
Al3+ shows only difference in the intensity of ECD spectra at 
higher Al3+ (1 : 5) concentration, while with Ca2+ ion (1 : 1) 
the ECD spectrum shows a typical β-sheet-like spectrum 
(conformational changes involving backbone amide 
carbonyls) with an additional band at 248 nm. 
 Compounds 1, 2 and 4 gave the same ECD shape but 
at different peptide / Zn2+ ratios. Primarily binding of Zn2+ 
to the OH-group of side chains (Tyr) and C-terminus 
carboxyl group is responsible for stabilizing the structure, 
leading to higher distribution of ordered structures. The C-
like spectrum in the case of compound 3 can reflect a 
mixture of the different turn types, e.g. βI/III. 
 ECD spectra of compounds 2, 4 and 5 show no 
changes during titration with Pb2+. The ECD spectrum of 
compound 1 with Pb2+ shows conformational changes, 
mainly formation of βI/III type turns and also a positive 
band at ~ 240 nm. Compound 3 with Pb2+ gave βI/III turn-
type ECD shape, similar to that with Zn2+. 
 Complexation of compounds 1 and 5 with Cu2+ 
results in an increase of the population of ordered 
structures. In the case of compounds 2 and 4 the changes 
in the ECD spectra reflect the increase of the ordered 
structures and appearance of the band at ~ 245 nm. The 
measured ECD spectra of compound 3-Cu2+ complexes 
show typical features of a mixture of βI/III- and γ-turns 
which correlate with the changes produced by Pb2+ and Zn2+ 
upon complexation with compound 3. 
 The conformational changes of compounds 1–5 can 
include self-aggregation and consequently alterations in 
physicochemical properties and biostability of natural 
compounds having interesting biological activities from the 
medicinal chemistry viewpoint. 
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